The estimated Net Worth of Robert F Byrnes is at least $260 Tausend dollars as of 12 February 2016. Mr. Byrnes owns over 10,999 units of Revance Therapeutics Inc stock worth over $72,373 and over the last 11 years he sold RVNC stock worth over $0. In addition, he makes $187,947 as Independent Director at Revance Therapeutics Inc.
Robert has made over 3 trades of the Revance Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 10,999 units of RVNC stock worth $44,216 on 12 February 2016.
The largest trade he's ever made was exercising 10,999 units of Revance Therapeutics Inc stock on 12 February 2016 worth over $44,216. On average, Robert trades about 1,897 units every 39 days since 2014. As of 12 February 2016 he still owns at least 10,999 units of Revance Therapeutics Inc stock.
You can see the complete history of Mr. Byrnes stock trades at the bottom of the page.
Robert F. Byrnes serves as Independent Director of the Company. Mr. Byrnes has served as a director of our Company since August 2004. Mr. Byrnes has spent over forty years in the medical device and biotechnology industries. From October 1997 until October 2002, and from January 2005 to the present, Mr. Byrnes has served as the President and Chief Executive Officer of Roan Advisors, Inc., an advisory service for healthcare organizations. From November 2002 to January 2005, he served as the President and Chief Executive Officer of Thermage, Inc., a medical device company focused on non-invasive tissue tightening. Mr. Byrnes has also served as Chairman and Chief Executive Officer of Tokos Medical Corporation, a healthcare services company, President of Caremark, Inc., a home healthcare service company, and Vice President of Marketing and Business Development for Genentech, Inc., a biotechnology company. He currently serves on the board of directors of Allego Ophthalmics, LLC. Mr. Byrnes holds a B.S. in Pharmacy from Ferris State University and an M.B.A. degree in Marketing and Finance from Loyola University, Chicago. Our board of directors believes that Mr. Byrnes’s operating experience in the medical device and biotechnology industries, combined with his prior board positions, make him qualified to serve on our board of directors.
As the Independent Director of Revance Therapeutics Inc, the total compensation of Robert Byrnes at Revance Therapeutics Inc is $187,947. There are 11 executives at Revance Therapeutics Inc getting paid more, with Mark Foley having the highest compensation of $17,190,400.
Robert Byrnes is 75, he's been the Independent Director of Revance Therapeutics Inc since 2004. There are no older and 15 younger executives at Revance Therapeutics Inc.
Robert's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK, CA, 94560.
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli und Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Revance Therapeutics Inc executives and other stock owners filed with the SEC include: